{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:33:05Z","timestamp":1783531985857,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.clml.2014.04.015","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T17:51:23Z","timestamp":1417801883000},"page":"S6-S13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S","title":["Humoral and Cellular Immunotherapy in ALL in\u00a0Children, Adolescents, and Young Adults"],"prefix":"10.1016","volume":"14","author":[{"given":"Jessica","family":"Hochberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader Kim","family":"El-Mallawany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.04.015_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood.V73.6.1720.1720","article-title":"Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia","volume":"73","author":"Sullivan","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.015_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/bmt.2008.259","article-title":"Donor lymphocyte infusions: the long and winding road: how should it be traveled?","volume":"42","author":"Tomblyn","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2014.04.015_bib5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib6","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.015_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.04.015_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A\u00a0study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2014.04.015_bib9","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.clml.2014.04.015_bib10","doi-asserted-by":"crossref","first-page":"9536","DOI":"10.1200\/jco.2010.28.15_suppl.9536","article-title":"Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III\/IV (Group B) and BM+\/CNS+ (Group C) mature B-NHL: a Children's Oncology Group report (abstract)","volume":"28","author":"Cairo","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.015_bib11","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood.V118.21.2702.2702","article-title":"The efficacy of rasburicase and rituximab combined with FAB chemotherapy in children and adolescents with newly diagnosed stage III\/IV, BM+ and CNS+ mature B-NHL: a children's oncology group report (abstract)","volume":"21","author":"Goldman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib12","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1055\/s-2006-942273","article-title":"Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL","volume":"218","author":"Gudowius","year":"2006","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.clml.2014.04.015_bib13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clml.2014.04.015_bib14","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.015_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood.V118.21.573.573","article-title":"Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from children's oncology group (COG) study ADVL04P2 (abstract)","volume":"118","author":"Raetz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2014.04.015_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2141.2010.08251.x","article-title":"Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia","volume":"150","author":"Mussai","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.04.015_bib18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood.V118.21.248.248","article-title":"A\u00a0novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL) (abstract)","volume":"118","author":"Wayne","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11899-009-0024-3","article-title":"Update on developmental therapeutics for acute lymphoblastic leukemia","volume":"4","author":"Smith","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2014.04.015_bib20","first-page":"4038","article-title":"Superior antitumor activity of\u00a0SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma","volume":"15","author":"Al-Katib","year":"2009","journal-title":"Clin\u00a0Cancer Res"},{"key":"10.1016\/j.clml.2014.04.015_bib21","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1078-0432.CCR-12-3613","article-title":"The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia","volume":"19","author":"Carol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2014.04.015_bib22","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","article-title":"Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.015_bib23","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.clml.2014.04.015_bib24","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.015_bib25","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","article-title":"Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in\u00a0B-lineage ALL","volume":"120","author":"Topp","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood.V122.21.70.70","article-title":"A\u00a0phase 1\/2 study of blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia (abstract)","volume":"122","author":"von Stackelberg","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib27","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1182\/blood-2006-04-016709","article-title":"Prognostic significance of CD20 expression in\u00a0childhood B-cell precursor acute lymphoblastic leukemia","volume":"108","author":"Jeha","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.bmt.1702706","article-title":"Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia","volume":"27","author":"Jandula","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2014.04.015_bib29","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.015_bib30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2141.2011.08966.x","article-title":"Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma","volume":"156","author":"Barth","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.04.015_bib31","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib33","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1182\/blood-2006-04-020057","article-title":"Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab","volume":"108","author":"Bowles","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib34","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1182\/blood.V120.21.4865.4865","article-title":"Obinutuzumab (GA101) significantly enhances cell death and ADCC compared to rituximab against CD20+ sensitive and rituximab resistant b-cell non-Hodgkin lymphoma (NHL) and lymphoblastic leukemia (BLL) (abstract)","volume":"120","author":"Tiwari","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib36","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V114.22.1704.1704","article-title":"Phase I study of RO5072759 (GA101) in\u00a0patients with relapsed\/refractory CD20+ non-Hodgkin lymphoma (NHL) (abstract)","volume":"114","author":"Salles","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood.V118.21.270.270","article-title":"Obinutuzumab (GA101) in combination with FC or CHOP in patients with relapsed or refractory follicular lymphoma: final results of the phase I GAUDI study (BO21000) (abstract)","volume":"118","author":"Radford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib38","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood.V118.21.3655.3655","article-title":"Encouraging activity of obinutuzumab (GA101) monotherapy in relapsed\/refractory aggressive non-Hodgkin's lymphoma: results from a phase II study (BO20999) (abstract)","volume":"118","author":"Morschhauser","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib39","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1182\/blood.V122.21.3068.3068","article-title":"Obinutuzumab (GA101) significantly improves survival in CD20-positive pre-B cell lymphoblastic leukemia (pre-B-ALL) xenograft models compared to rituximab (RTX): potential targeted therapy in patients with high risk pre-B-ALL","author":"Awasthi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib40","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pbc.22209","article-title":"A\u00a0phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report","volume":"53","author":"Angiolillo","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2014.04.015_bib41","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.2009.008649","article-title":"Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission","volume":"94","author":"Patel","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.04.015_bib42","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1182\/blood-2012-01-405795","article-title":"Impact of immune modulation with in\u00a0vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia","volume":"119","author":"Veys","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib43","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1158\/0008-5472.CAN-04-2756","article-title":"Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7","volume":"65","author":"Bremer","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2014.04.015_bib44","first-page":"956304","article-title":"Chimeric antigen receptor-engineered T cells for immunotherapy of cancer","volume":"2010","author":"Cartellieri","year":"2010","journal-title":"J\u00a0Biomed Biotechnol"},{"key":"10.1016\/j.clml.2014.04.015_bib45","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib46","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1158\/0008-5472.CAN-04-0454","article-title":"Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells","volume":"64","author":"Kahlon","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2014.04.015_bib47","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood-2010-01-043737","article-title":"Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor","volume":"116","author":"Jena","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hem.V10.5.1040","article-title":"Treatment of B-ALL with CD-19-specific chimeric antigen receptor T cells","volume":"10","author":"Tothova","year":"2013","journal-title":"Hematologist"},{"key":"10.1016\/j.clml.2014.04.015_bib49","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2005-09-3904","article-title":"Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy","volume":"107","author":"Serrano","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.015_bib51","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib52","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.015_bib53","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2014.04.015_bib54","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V120.21.3007.3007","article-title":"Expanded natural killer (NK) cells transfected with anti-CD20 chimeric antigen receptor (CAR) mRNA have significant cytotoxicity against poor risk B-cell (CD20+) leukemia\/lymphoma (B-L\/L) (abstract)","volume":"120","author":"Chu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib55","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood.V122.21.3263.3263","article-title":"Anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells significantly mediate Burkitt lymphoma (BL) regression and improve survial in human BL xenografted NSG mice (abstract)","volume":"122","author":"Chu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.015_bib56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12002","article-title":"The future role of monoclonal antibody therapy in childhood acute leukaemias","volume":"159","author":"Barth","year":"2012","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501400161X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501400161X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:21Z","timestamp":1761870441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501400161X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":56,"alternative-id":["S215226501400161X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.04.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral and Cellular Immunotherapy in ALL in\u00a0Children, Adolescents, and Young Adults","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}